Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.
Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.
The fifth edition of Oncology Insights, a research-based report series analyzing the views of more than 180 U.S. oncologists, from Cardinal Health Specialty Solutions, found that overall, participating oncologists are optimistic AI will improve both patient care and practice operations.
When asked about the future impact of AI on the oncology industry, 53% of participating oncologists said they are “excited.” More than half of oncologists said they anticipate AI will help enhance the quality of care (53%), improve clinical outcomes (57%), and drive operational efficiencies (58%) in three or more years. Nearly half (47%) also expect it to lower the cost of care.
“The potential of AI-based tools to improve care and lower healthcare costs is significant,” says Bruce Feinberg, DO, vice president and chief medical officer for Cardinal Health Specialty Solutions.
As evidence of this, public and private investment in healthcare AI is expected to reach $6.6 billion by 2021, according to Forbes.
Related: Three Reasons AI Is ‘Wildly Different’ Than Other Healthcare Technologies
“Healthcare systems will play a key role in the early adoption and use of this technology,” Feinberg says. “Our research may help healthcare executives better understand the expectations and concerns oncologists have about these tools, and identify potential barriers that will need to be addressed as new technology is introduced into practice.”
Unique findings
Other report findings include:
“The potential breakthroughs in oncology treatment make this the most exciting time in history to provide care to cancer patients,” Feinberg says. “At the same time, oncologists face unprecedented challenges including growing patient volumes, rising costs, increasing regulatory pressures, increasing industry consolidation, and changing reimbursement models. Emerging tools such as AI have the potential to help ease some of these burdens for oncologists-but, if not understood and used effectively, they could also add to the complexity.”
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
In the Scope of Virtual Health and the Future of “Website” Manner, Per Ateev Mehrotra
August 10th 2023Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center.
Listen